What Sertraline does
Sertraline is among the most prescribed antidepressants in the US. It blocks serotonin reuptake in the brain, improving mood, anxiety, and obsessional symptoms over several weeks. It is considered first-line for depression and anxiety in most current guidelines.
What the evidence says for Black patients
SSRIs as a class have more complex race-specific evidence than cardiovascular drugs. Three themes matter:
- Response rates. Post-hoc analyses of STAR*D (Lesser et al., J Clin Psychiatry 2007) and other large antidepressant effectiveness trials have shown mixed race-based response signals. Some analyses suggest slightly lower remission rates in Black participants treated with citalopram alone; others show no significant difference when confounders (income, insurance continuity, stigma-driven under-reporting) are controlled. The honest summary is that efficacy differences are small at best and largely explained by social factors.
- CYP2D6 and CYP2C19 pharmacogenomics. Sertraline is metabolized mainly by CYP2C19 (and to a lesser degree 2B6 and 3A4). CYP2C19 poor metabolizers, common in Black populations for some allele patterns, may have higher sertraline levels and more side effects at standard doses. Hicks et al. (Clin Pharmacol Ther 2015;98:127 to 34) summarize CPIC dosing guidance.
- Access and discontinuation. Black adults with depression are less likely to receive any antidepressant treatment, less likely to be referred to psychotherapy, and more likely to discontinue medication early than white adults with comparable diagnoses (Alegría et al., Psychiatr Serv 2008;59:1264 to 72; Lê Cook et al., Med Care 2014;52:S4 to S11). Side-effect counseling, expectation-setting, and cultural-competency of the clinician strongly affect whether a patient stays on the drug long enough to respond.
How your genes can change this drug
Some people process sertraline differently because of an inherited gene variant, and the difference is large enough that prescribing guidelines address it. The recommendations below are published by CPIC, the Clinical Pharmacogenetics Implementation Consortium, and are quoted as written. They are guidance for prescribers, not instructions to change your own dose.
Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose. Initiate therapy with recommended starting dose. Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19 or CYP2B6. Initiate therapy with recommended starting dose Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6. Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than normal metabolizers. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2B6 normal metabolizers Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2C19 normal metabolizers. Consider a lower starting dose, slower titration schedule and 50% reduction of standard maintenance dose as compared to CYP2C19 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. Select an alternative antidepressant not primarily metabolized by CYP2C19 or CYP2B6. No recommendation Consider a lower starting dose, slower titration schedule and 25% reduction of standard maintenance dose as CYP2B6 normal metabolizers or select a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2B6. Initiate therapy with recommended starting dose. Consider a slower titration schedule and lower maintenance dose than CYP2B6 normal metabolizers.
Genetic testing for these variants is available but is not routine. If you have had a reaction to this drug, or it has not worked for you, this is worth raising with your prescriber. Do not stop or change a prescription on your own.
Common alternatives
Escitalopram (Lexapro), fluoxetine (Prozac), and bupropion (Wellbutrin) are other first-line options. Bupropion is notable for not causing sexual dysfunction and for aiding smoking cessation, relevant for Black patients with comorbid nicotine use.
Side effects
- Nausea, GI upset (most common in first 2 weeks)
- Sexual dysfunction (decreased libido, delayed orgasm)
- Sleep disturbance
- Weight gain (modest with long-term use)
- Hyponatremia (older adults)
- Boxed warning, increased suicidality risk in adolescents and young adults in the first weeks
- Serotonin syndrome if combined with MAOIs, triptans, tramadol, linezolid
- Discontinuation syndrome (shorter half-life, not as severe as paroxetine, but real; do not stop abruptly)
Factors that affect adherence
The 2 to 6 week delay in response, combined with early side effects, drives early discontinuation, especially in Black patients who may have higher baseline skepticism from historical medical mistrust. Explicit expectation-setting ('you may feel worse before better for 2 weeks') and a 2-week follow-up call improve continuation. Generic sertraline is inexpensive and widely covered.
Questions to ask your doctor
Bring this list to your next appointment.
- How long should I stay on this once I feel better?
- What side effects should I expect in the first 2 weeks, and which are red flags?
- If I don't feel better in 6 weeks, what's the plan?
- Are there drug interactions I should know about, including with over-the-counter supplements?
- Is talk therapy available and covered?
References
- Lesser IM, Myers HF, Lin KM, et al. Ethnic differences in antidepressant treatment response of depressed women outpatients. J Clin Psychiatry. 2007;68:1178 to 1183.
- Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98:127 to 134.
- Alegría M, Chatterji P, Wells K, et al. Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr Serv. 2008;59:1264 to 1272.
- Lê Cook B, Zuvekas SH, Carson N, et al. Assessing racial/ethnic disparities in treatment across episodes of mental health care. Med Care. 2014;52:S4 to S11.
- U.S. Food and Drug Administration. Zoloft (sertraline hydrochloride) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019839s089s090lbl.pdf
Medical disclaimer
This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients, it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.
Read our editorial standards for how we source, review, and update these pages.